Sanofi $SNY Shares Acquired by Willis Investment Counsel

Willis Investment Counsel lifted its position in shares of Sanofi (NASDAQ:SNY) by 8.5% during the fourth quarter, HoldingsChannel reports. The firm owned 604,000 shares of the company’s stock after purchasing an additional 47,300 shares during the quarter. Sanofi comprises about 1.5% of Willis Investment Counsel’s holdings, making the stock its 21st largest holding. Willis Investment Counsel’s holdings in Sanofi were worth $29,270,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in SNY. Raymond James Financial Inc. raised its holdings in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares in the last quarter. Mondrian Investment Partners LTD acquired a new stake in Sanofi in the third quarter valued at $171,742,000. Natixis Advisors LLC raised its holdings in Sanofi by 11.8% in the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock valued at $146,952,000 after acquiring an additional 327,569 shares in the last quarter. Equity Investment Corp raised its holdings in Sanofi by 3.0% in the third quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock valued at $122,139,000 after acquiring an additional 75,255 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in Sanofi by 19.4% in the third quarter. American Century Companies Inc. now owns 2,338,969 shares of the company’s stock valued at $110,399,000 after acquiring an additional 379,784 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 0.7%

SNY stock opened at $47.14 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1-year low of $43.32 and a 1-year high of $55.73. The firm has a fifty day moving average price of $46.46 and a two-hundred day moving average price of $48.01. The firm has a market cap of $114.97 billion, a price-to-earnings ratio of 13.09, a PEG ratio of 1.19 and a beta of 0.42.

Analysts Set New Price Targets

Several analysts recently issued reports on SNY shares. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. HSBC reaffirmed a “buy” rating on shares of Sanofi in a report on Wednesday, December 10th. Citigroup started coverage on shares of Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Finally, Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $61.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.